Calumet, Inc. $CLMT Shares Purchased by O Keefe Stevens Advisory Inc.

O Keefe Stevens Advisory Inc. raised its position in Calumet, Inc. (NASDAQ:CLMTFree Report) by 12.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,817 shares of the oil and gas company’s stock after acquiring an additional 2,903 shares during the quarter. O Keefe Stevens Advisory Inc.’s holdings in Calumet were worth $423,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Caldwell Sutter Capital Inc. grew its position in Calumet by 29.9% in the second quarter. Caldwell Sutter Capital Inc. now owns 19,483 shares of the oil and gas company’s stock valued at $307,000 after acquiring an additional 4,483 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Calumet by 33.5% in the first quarter. Goldman Sachs Group Inc. now owns 465,269 shares of the oil and gas company’s stock valued at $5,900,000 after acquiring an additional 116,777 shares in the last quarter. Adams Asset Advisors LLC grew its position in Calumet by 0.9% in the second quarter. Adams Asset Advisors LLC now owns 5,406,271 shares of the oil and gas company’s stock valued at $85,176,000 after acquiring an additional 49,948 shares in the last quarter. Finally, Wasserstein Debt Opportunities Management L.P. grew its position in Calumet by 3.2% in the second quarter. Wasserstein Debt Opportunities Management L.P. now owns 5,817,012 shares of the oil and gas company’s stock valued at $91,647,000 after acquiring an additional 180,197 shares in the last quarter. Institutional investors and hedge funds own 34.41% of the company’s stock.

Calumet Stock Performance

CLMT stock opened at $18.59 on Friday. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of -3.56 and a beta of 0.98. Calumet, Inc. has a 1 year low of $7.68 and a 1 year high of $25.29. The stock’s fifty day moving average is $16.55 and its two-hundred day moving average is $14.52.

Calumet (NASDAQ:CLMTGet Free Report) last posted its earnings results on Friday, August 8th. The oil and gas company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($1.26). The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $982.88 million. The business’s revenue was down 9.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.48) EPS. As a group, analysts predict that Calumet, Inc. will post -3.02 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CLMT. UBS Group increased their price objective on shares of Calumet from $12.00 to $13.25 and gave the company a “neutral” rating in a research report on Tuesday, August 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Calumet in a research report on Saturday, September 27th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $18.71.

View Our Latest Stock Analysis on Calumet

Calumet Profile

(Free Report)

Calumet, Inc engages in the manufacturing, formulating, and marketing of a diversified slate of specialty branded products and renewable fuels to customers across a broad range of consumer-facing and industrial markets. It operates through the following segments: Specialty Products & Solutions, Performance Brands, Montana/Renewables, and Corporate.

See Also

Want to see what other hedge funds are holding CLMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Calumet, Inc. (NASDAQ:CLMTFree Report).

Institutional Ownership by Quarter for Calumet (NASDAQ:CLMT)

Receive News & Ratings for Calumet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calumet and related companies with MarketBeat.com's FREE daily email newsletter.